罗格列酮对2型糖尿病内皮依赖性血管舒张功能的影响  

Effect of rosiglitazone on endothelium-dependent vasodilatation of type 2 diabetes mellitus

作　　者：林霞[1] 黄鄖 

机构地区：[1]浙江省湖州市第一人民医院内分泌科,浙江湖州313000 [2]浙江大学医学院附属邵逸夫医院心内科,浙江杭州310058

出　　处：《中国现代医生》2013年第14期56-58,61,共4页China Modern Doctor

基　　金：国家自然科学基金(81000064)

摘　　要：目的探讨罗格列酮对2型糖尿病内皮依赖性血管舒张功能的影响。方法选择2型糖尿病患者60例为研究对象,分别给予二甲双胍、二甲双胍联合罗格列酮、罗格列酮治疗,另选择20例健康体检者作为对照组,回顾性分析治疗前后三组内皮依赖性血管舒张功能及其他相关指标变化。结果联合组和罗格列酮组HDL-C治疗前后比较,差异有统计学意义(P<0.05)。治疗后三组FPG、HbA1c、FINS、HOMR-IR与治疗前比较,差异有统计学意义(P<0.05)。联合组和罗格列酮组NO、高敏C反应蛋白、TNF-α治疗后各指标与治疗前比较差异有统计学意义(P<0.05)。联合组和罗格列酮组治疗后FMD和EID与治疗前比较,差异有统计学意义(P<0.05)。结论 2型糖尿病患者存在血管内皮依赖性舒张功能受损,罗格列酮能够升高NO水平,改善内皮依赖性舒张功能,从而对血管发挥保护作用。Objective To discuss effect of rosiglitazone on endothelium-dependent vasodilatation of type 2 diabetes mellitus. Methods Selected 60 cases with type 2 diabetes mellitus were devided into 3 groups, and treated vyith melbine, melbine combined with rosiglitazone, rosiglitazone separately. 20 cases healthy volunteers were selected as control group. Endothelium-dependent vasodilatation and another index were compared. Results HDL-C of combined group and rosiglitazone group had significant differents （P 〈 0.05）. FPG,HbAlc ,FINS,HOMR-IR of three groups after therapy had significant difference with before therapy （P 〈 0.05）. NO,hs-CRP,TNF-αof combined group and rosiglitazone group after therapy had significant difference with before therapy （P 〈 0.05）. FMD and EID of combined group and rosiglitazone group after therapy had significant difference with before therapy （P 〈 0.05）. Conclusion Patients with type 2 diabetes mellitus show endothelium-dependent vasodilatation destroy. Rosiglitazone can improve NO, and improve endothelium-dependent vasodilatation, then protect vessel.

关 键 词：罗格列酮 2型糖尿病 内皮依赖性血管舒张功能 

分 类 号：R587.1[医药卫生—内分泌]